William Sullivan has been ap-pointed vice president of diagnostics operations at Ciphergen’s new diagnostics division. Before joining Ciphergen, he was vice president of diagnostic manufacturing at Visible Genetics. Sullivan holds an AB degree from the College of the Holy Cross and attended graduate school at the University of Pennsylvania.
Kevin Johnson and Giannni Garotta have joined European venture capital firm Index Ventures as executives in residence, and Ennio Ongini as venture advisor. Johnson was most recently chief technology officer of Cambridge Antibody Technologies. Garotta used to be vice president for academic collaborations at Serono. Ongini is cur-rently head of discovery at Nicox.
Randy Jones has been named director of toxicology for the Arkansas discovery and development services division of Charles River Laboratories. Jones previously held a regulatory affairs management position at Primus. Prior to that, he spent 10 years as senior toxicologist at Bayer. He holds a PhD from the University of Georgia and a doctorate of veterinary medicine from Iowa State University.